Compare CBSH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBSH | PRAX |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 9.6B |
| IPO Year | 2008 | 2020 |
| Metric | CBSH | PRAX |
|---|---|---|
| Price | $48.31 | $301.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $60.56 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.2M | 328.9K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 4.39 | N/A |
| EPS | ★ 4.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.55 | N/A |
| Revenue Next Year | $3.38 | $6,395.88 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $48.73 | $26.70 |
| 52 Week High | $66.31 | $354.87 |
| Indicator | CBSH | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 39.85 |
| Support Level | N/A | $290.36 |
| Resistance Level | $55.09 | $322.32 |
| Average True Range (ATR) | 1.34 | 17.69 |
| MACD | -0.45 | -5.16 |
| Stochastic Oscillator | 3.81 | 14.99 |
Commerce Bancshares Inc operates as the bank holding company for Commerce Bank. The bank is engaged in the general banking business, providing a broad range of retail, mortgage banking, corporate, investment, trust, and asset management products and services to individuals, businesses, and municipalities. It operates through three segments: Consumer, Commercial, and Wealth. The Commercial segment provides corporate lending, payment solutions, leasing, international services, and business banking. The Consumer segment covers retail banking, mortgages, installment lending, and card services. The Wealth segment offers trust and estate planning, brokerage, and investment management services.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.